查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1589533

直接面向消费者的基因检测市场：按类型、管道和功能划分 - 2025-2030 年全球预测

Direct-to-Consumer Genetic Testing Market by Type (Mitochondrial DNA Testing, Single Nucleotide Polymorphism Testing, Y Chromosome Testing), Channel (Offline, Online), Function - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年直接面向消费者的基因检测市场价值为20.2亿美元，预计2024年将达到23.6亿美元，复合年增长率为17.21%，到2030年将达到61.5亿美元。

直接面向消费者 (DTC) 的基因检测使消费者无需直接参与医疗保健专业人员即可获得基因检测服务，使个人能够直接了解自己的血统、健康风险和倾向。消费者对个人化健康资讯和主动健康管理的兴趣日益增长，推动了对此类服务的需求。这些测试可应用于多个领域，包括谱系研究、遗传疾病易感性筛检以及个人化饮食和健身计划。主要最终使用者是注重健康的个人、系谱和注重健康、寻求对其遗传资讯拥有更大自主权的企业。基因研究的进步、定序技术成本的降低以及消费者意识和对个人化医疗解决方案的需求的提高对市场成长产生了重大影响。然而，该市场也面临一些障碍，例如对资料隐私的担忧、复杂的监管环境以及在没有专家指导的情况下遗传资料可能被误解的可能性。儘管存在这些挑战，但仍有很大的机会来扩大有关使用遗传资讯的消费者教育、制定强有力的资料隐私措施以及整合人工智慧以增强资料解释。公司可以透过投资透明的资料保护通讯协定、与医疗保健专业人员合作提供客户指导以及透过全面的教育倡议来提高客户参与来利用这些机会。研究和创新应专注于提高测试准确性、扩大健康状况的覆盖范围以及开髮用户友好的平台，将遗传见解整合到可行的医疗保健计划中。 DTC 基因检测市场的本质是动态的和消费者主导的，其特点是技术的快速采用和解决现有限制和市场需求的巨大创新空间。优先考虑道德因素并专注于提供可靠且可行的见解的公司将处于有利地位，能够在这个不断发展的市场中实现持续成长。

主要市场统计
基准年[2023] 20.2亿美元
预测年份 [2024] 23.6亿美元
预测年份 [2030] 61.5亿美元
复合年增长率（%） 17.21%

市场动态：揭示快速发展的直接面向消费者的基因检测市场的关键市场洞察

供需的动态交互作用正在改变直接面向消费者的基因检测市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，并了解消费行为及其对製造成本的影响，并更清楚地了解对采购趋势的影响。

  • 市场驱动因素
    • 随着消费者寻求对自己的医疗保健有更多控制权，模式转移
    • 提高对基因组检测和遗传疾病风险的认识
    • 高龄化社会的进展与慢性病的蔓延
    • 对评估血统和祖先的好奇心不断增加
  • 市场限制因素
    • 相关科学、技术和临床问题
    • 第一修正案关于广告中的诚实、忠于事实和真相的问题
  • 市场机会
    • 用于当前和未来基因诊断的次世代定序仪和生物晶片
    • 开发满足客户需求的线上应用程式
  • 市场挑战
    • 测试结果解释的复杂性
    • 医生缺乏足够的遗传学知识

波特五力：驾驭直接面向消费者的基因检测市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势、解决弱点并避免潜在的挑战，以确保更强大的市场地位。

PESTLE分析：了解直接面向消费者的基因检测市场的外部影响

外部宏观环境因素在塑造直接面向消费者的基因检测市场表现动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解直接面向消费者的基因检测市场的竞争格局

对直接面向消费者的基因检测市场的详细市场占有率分析可以对供应商绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示自己的竞争定位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵供应商在直接面向消费者的基因检测市场的绩效评估

FPNV定位矩阵是评估直接面向消费者的基因检测市场供应商的关键工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议，为直接面向消费者的基因检测市场制定成功之路

对于旨在加强其在全球市场的影响力的公司来说，对直接面向消费者的基因检测市场进行策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 模式转移：消费者希望更好地控制他们的医疗保健管理
      • 提高对基因组检测和遗传疾病风险的认识
      • 随着人口不断老化，慢性病的发生率也增加。
      • 人们对评估血统和血统的兴趣日益浓厚
    • 抑制因素
      • 相关科学、技术和临床问题
      • 第一修正案关于广告中的诚实、事实忠实和真相的问题
    • 机会
      • 用于当前和未来基因诊断的次世代定序和生物晶片
      • 开发满足客户需求的线上应用程式
    • 任务
      • 解释测试结果的复杂性
      • 医生缺乏足够的遗传学知识
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章 直接面向消费者的基因检测市场：依类型

  • 粒线体DNA测试
  • 单核苷酸多态性检测
  • Y染色体测试

第七章 直接面向消费者的基因检测市场：按管道

  • 离线
  • 在线的

第八章 直接面向消费者的基因检测市场：依功能分类

  • 血统和种族
  • 癌症筛检
    • 遗传性癌症
      • 血癌
      • 乳癌
      • 卵巢癌
    • 散发性癌症
  • 遗传疾病带因者状况
  • 新生儿筛检
  • 特征
  • 健康

第九章 美洲直接面向消费者的基因检测市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太地区直接面向消费者的基因检测市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章 欧洲、中东和非洲直接面向消费者的基因检测市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Ancestry.com LLC
  • Dante Labs Inc.
  • EasyDNA
  • FamilyTreeDNA by Gene, Ltd.
  • Genesis Healthcare Co.
  • Helix OpCo, LLC
  • Karmagenes SA
  • Living DNA Ltd.
  • Mapmygenome
  • Merck KGaA
  • MyHeritage Ltd.
  • Positive Biosciences, Ltd.
  • Shuwen Biotech Co. Ltd.
  • Vitagene, Inc.
  • Xcode Life
Product Code: MRR-4312A385A4B9

The Direct-to-Consumer Genetic Testing Market was valued at USD 2.02 billion in 2023, expected to reach USD 2.36 billion in 2024, and is projected to grow at a CAGR of 17.21%, to USD 6.15 billion by 2030.

Direct-to-consumer (DTC) genetic testing allows consumers to access genetic testing services without the direct involvement of healthcare professionals, enabling individuals to obtain insights into ancestry, health risks, and predispositions directly. The necessity for such services is driven by the increasing consumer interest in personalized health information and proactive health management. These tests hold application across several domains, including genealogical research, predisposition screening for hereditary diseases, and personalized diet and fitness planning. The primary end-users are health-conscious individuals seeking greater autonomy over their genetic information, genealogists, and wellness-oriented companies. Market growth is significantly influenced by advancements in genetic research, cost reductions in sequencing technologies, and rising consumer awareness and demand for personalized healthcare solutions. However, the market also faces hurdles such as concerns surrounding data privacy, regulatory landscape complexities, and the potential for misinterpretation of genetic data without professional guidance. Despite these challenges, there lies a substantial opportunity in expanding consumer education on genetic information usage, developing robust data privacy measures, and integrating AI for enhanced data interpretation. Companies can capitalize on these opportunities by investing in transparent data protection protocols, collaborating with healthcare professionals for customer guidance, and enhancing customer engagement through comprehensive education initiatives. Research and innovation should focus on advancing test accuracy, expanding the scope of health conditions covered, and developing user-friendly platforms that integrate genetic insights into actionable healthcare plans. The nature of the DTC genetic testing market is dynamic and consumer-driven, characterized by rapid technological adoption and a significant scope for innovation to address existing limitations and market demands. Companies that prioritize ethical considerations and focus on delivering reliable and actionable insights will be well-positioned for sustained growth in this evolving market.

KEY MARKET STATISTICS
Base Year [2023] USD 2.02 billion
Estimated Year [2024] USD 2.36 billion
Forecast Year [2030] USD 6.15 billion
CAGR (%) 17.21%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Direct-to-Consumer Genetic Testing Market

The Direct-to-Consumer Genetic Testing Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Paradigm shift among consumers seeking greater control over their own healthcare
    • Rising awareness about genome testing and risk of genetic diseases
    • High aging population coupled with growing prevalence of chronic disorders
    • Increased inquisitiveness about the assessment of lineage and ancestry
  • Market Restraints
    • Related scientific, technical, and clinical issues
    • First amendment issues of honesty, fidelity to facts, and truth-in-advertising
  • Market Opportunities
    • Next-generation sequencing and bio-chip for present and future genetic diagnosis
    • Development of online applications to serve customer needs
  • Market Challenges
    • Complexity of test result interpretation
    • Lack of adequate physician knowledge about genetics

Porter's Five Forces: A Strategic Tool for Navigating the Direct-to-Consumer Genetic Testing Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Direct-to-Consumer Genetic Testing Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Direct-to-Consumer Genetic Testing Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Direct-to-Consumer Genetic Testing Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Direct-to-Consumer Genetic Testing Market

A detailed market share analysis in the Direct-to-Consumer Genetic Testing Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Direct-to-Consumer Genetic Testing Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Direct-to-Consumer Genetic Testing Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Direct-to-Consumer Genetic Testing Market

A strategic analysis of the Direct-to-Consumer Genetic Testing Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Direct-to-Consumer Genetic Testing Market, highlighting leading vendors and their innovative profiles. These include Ancestry.com LLC, Dante Labs Inc., EasyDNA, FamilyTreeDNA by Gene, Ltd., Genesis Healthcare Co., Helix OpCo, LLC, Karmagenes SA, Living DNA Ltd., Mapmygenome, Merck KGaA, MyHeritage Ltd., Positive Biosciences, Ltd., Shuwen Biotech Co. Ltd., Vitagene, Inc., and Xcode Life.

Market Segmentation & Coverage

This research report categorizes the Direct-to-Consumer Genetic Testing Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Mitochondrial DNA Testing, Single Nucleotide Polymorphism Testing, and Y Chromosome Testing.
  • Based on Channel, market is studied across Offline and Online.
  • Based on Function, market is studied across Ancestry & Ethnicity, Cancer Screening, Genetic Disease Carrier Status, New Baby Screening, Traits, and Wellness. The Cancer Screening is further studied across Hereditary Cancer and Sporadic Cancer. The Hereditary Cancer is further studied across Blood Cancer, Breast Cancer, and Ovarian Cancer.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Paradigm shift among consumers seeking greater control over their own healthcare
      • 5.1.1.2. Rising awareness about genome testing and risk of genetic diseases
      • 5.1.1.3. High aging population coupled with growing prevalence of chronic disorders
      • 5.1.1.4. Increased inquisitiveness about the assessment of lineage and ancestry
    • 5.1.2. Restraints
      • 5.1.2.1. Related scientific, technical, and clinical issues
      • 5.1.2.2. First amendment issues of honesty, fidelity to facts, and truth-in-advertising
    • 5.1.3. Opportunities
      • 5.1.3.1. Next-generation sequencing and bio-chip for present and future genetic diagnosis
      • 5.1.3.2. Development of online applications to serve customer needs
    • 5.1.4. Challenges
      • 5.1.4.1. Complexity of test result interpretation
      • 5.1.4.2. Lack of adequate physician knowledge about genetics
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Direct-to-Consumer Genetic Testing Market, by Type

  • 6.1. Introduction
  • 6.2. Mitochondrial DNA Testing
  • 6.3. Single Nucleotide Polymorphism Testing
  • 6.4. Y Chromosome Testing

7. Direct-to-Consumer Genetic Testing Market, by Channel

  • 7.1. Introduction
  • 7.2. Offline
  • 7.3. Online

8. Direct-to-Consumer Genetic Testing Market, by Function

  • 8.1. Introduction
  • 8.2. Ancestry & Ethnicity
  • 8.3. Cancer Screening
    • 8.3.1. Hereditary Cancer
      • 8.3.1.1. Blood Cancer
      • 8.3.1.2. Breast Cancer
      • 8.3.1.3. Ovarian Cancer
    • 8.3.2. Sporadic Cancer
  • 8.4. Genetic Disease Carrier Status
  • 8.5. New Baby Screening
  • 8.6. Traits
  • 8.7. Wellness

9. Americas Direct-to-Consumer Genetic Testing Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Direct-to-Consumer Genetic Testing Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Direct-to-Consumer Genetic Testing Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Ancestry.com LLC
  • 2. Dante Labs Inc.
  • 3. EasyDNA
  • 4. FamilyTreeDNA by Gene, Ltd.
  • 5. Genesis Healthcare Co.
  • 6. Helix OpCo, LLC
  • 7. Karmagenes SA
  • 8. Living DNA Ltd.
  • 9. Mapmygenome
  • 10. Merck KGaA
  • 11. MyHeritage Ltd.
  • 12. Positive Biosciences, Ltd.
  • 13. Shuwen Biotech Co. Ltd.
  • 14. Vitagene, Inc.
  • 15. Xcode Life

LIST OF FIGURES

  • FIGURE 1. DIRECT-TO-CONSUMER GENETIC TESTING MARKET RESEARCH PROCESS
  • FIGURE 2. DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CHANNEL, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY FUNCTION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY FUNCTION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. DIRECT-TO-CONSUMER GENETIC TESTING MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. DIRECT-TO-CONSUMER GENETIC TESTING MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. DIRECT-TO-CONSUMER GENETIC TESTING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. DIRECT-TO-CONSUMER GENETIC TESTING MARKET DYNAMICS
  • TABLE 7. GLOBAL DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY MITOCHONDRIAL DNA TESTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY SINGLE NUCLEOTIDE POLYMORPHISM TESTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY Y CHROMOSOME TESTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY OFFLINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY ONLINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY ANCESTRY & ETHNICITY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CANCER SCREENING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY HEREDITARY CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY BLOOD CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY OVARIAN CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY HEREDITARY CANCER, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY SPORADIC CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CANCER SCREENING, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY GENETIC DISEASE CARRIER STATUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY NEW BABY SCREENING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY TRAITS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY WELLNESS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CANCER SCREENING, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY HEREDITARY CANCER, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 36. ARGENTINA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 37. ARGENTINA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CANCER SCREENING, 2018-2030 (USD MILLION)
  • TABLE 38. ARGENTINA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY HEREDITARY CANCER, 2018-2030 (USD MILLION)
  • TABLE 39. BRAZIL DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. BRAZIL DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 41. BRAZIL DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 42. BRAZIL DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CANCER SCREENING, 2018-2030 (USD MILLION)
  • TABLE 43. BRAZIL DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY HEREDITARY CANCER, 2018-2030 (USD MILLION)
  • TABLE 44. CANADA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. CANADA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 46. CANADA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 47. CANADA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CANCER SCREENING, 2018-2030 (USD MILLION)
  • TABLE 48. CANADA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY HEREDITARY CANCER, 2018-2030 (USD MILLION)
  • TABLE 49. MEXICO DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. MEXICO DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 51. MEXICO DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 52. MEXICO DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CANCER SCREENING, 2018-2030 (USD MILLION)
  • TABLE 53. MEXICO DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY HEREDITARY CANCER, 2018-2030 (USD MILLION)
  • TABLE 54. UNITED STATES DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. UNITED STATES DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 56. UNITED STATES DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 57. UNITED STATES DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CANCER SCREENING, 2018-2030 (USD MILLION)
  • TABLE 58. UNITED STATES DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY HEREDITARY CANCER, 2018-2030 (USD MILLION)
  • TABLE 59. UNITED STATES DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 60. ASIA-PACIFIC DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. ASIA-PACIFIC DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 62. ASIA-PACIFIC DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 63. ASIA-PACIFIC DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CANCER SCREENING, 2018-2030 (USD MILLION)
  • TABLE 64. ASIA-PACIFIC DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY HEREDITARY CANCER, 2018-2030 (USD MILLION)
  • TABLE 65. ASIA-PACIFIC DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 66. AUSTRALIA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. AUSTRALIA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 68. AUSTRALIA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 69. AUSTRALIA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CANCER SCREENING, 2018-2030 (USD MILLION)
  • TABLE 70. AUSTRALIA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY HEREDITARY CANCER, 2018-2030 (USD MILLION)
  • TABLE 71. CHINA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. CHINA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 73. CHINA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 74. CHINA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CANCER SCREENING, 2018-2030 (USD MILLION)
  • TABLE 75. CHINA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY HEREDITARY CANCER, 2018-2030 (USD MILLION)
  • TABLE 76. INDIA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. INDIA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 78. INDIA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 79. INDIA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CANCER SCREENING, 2018-2030 (USD MILLION)
  • TABLE 80. INDIA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY HEREDITARY CANCER, 2018-2030 (USD MILLION)
  • TABLE 81. INDONESIA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. INDONESIA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 83. INDONESIA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 84. INDONESIA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CANCER SCREENING, 2018-2030 (USD MILLION)
  • TABLE 85. INDONESIA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY HEREDITARY CANCER, 2018-2030 (USD MILLION)
  • TABLE 86. JAPAN DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. JAPAN DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 88. JAPAN DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 89. JAPAN DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CANCER SCREENING, 2018-2030 (USD MILLION)
  • TABLE 90. JAPAN DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY HEREDITARY CANCER, 2018-2030 (USD MILLION)
  • TABLE 91. MALAYSIA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. MALAYSIA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 93. MALAYSIA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 94. MALAYSIA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CANCER SCREENING, 2018-2030 (USD MILLION)
  • TABLE 95. MALAYSIA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY HEREDITARY CANCER, 2018-2030 (USD MILLION)
  • TABLE 96. PHILIPPINES DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. PHILIPPINES DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 98. PHILIPPINES DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 99. PHILIPPINES DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CANCER SCREENING, 2018-2030 (USD MILLION)
  • TABLE 100. PHILIPPINES DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY HEREDITARY CANCER, 2018-2030 (USD MILLION)
  • TABLE 101. SINGAPORE DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. SINGAPORE DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 103. SINGAPORE DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 104. SINGAPORE DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CANCER SCREENING, 2018-2030 (USD MILLION)
  • TABLE 105. SINGAPORE DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY HEREDITARY CANCER, 2018-2030 (USD MILLION)
  • TABLE 106. SOUTH KOREA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. SOUTH KOREA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 108. SOUTH KOREA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 109. SOUTH KOREA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CANCER SCREENING, 2018-2030 (USD MILLION)
  • TABLE 110. SOUTH KOREA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY HEREDITARY CANCER, 2018-2030 (USD MILLION)
  • TABLE 111. TAIWAN DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. TAIWAN DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 113. TAIWAN DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 114. TAIWAN DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CANCER SCREENING, 2018-2030 (USD MILLION)
  • TABLE 115. TAIWAN DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY HEREDITARY CANCER, 2018-2030 (USD MILLION)
  • TABLE 116. THAILAND DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. THAILAND DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 118. THAILAND DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 119. THAILAND DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CANCER SCREENING, 2018-2030 (USD MILLION)
  • TABLE 120. THAILAND DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY HEREDITARY CANCER, 2018-2030 (USD MILLION)
  • TABLE 121. VIETNAM DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. VIETNAM DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 123. VIETNAM DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 124. VIETNAM DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CANCER SCREENING, 2018-2030 (USD MILLION)
  • TABLE 125. VIETNAM DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY HEREDITARY CANCER, 2018-2030 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CANCER SCREENING, 2018-2030 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY HEREDITARY CANCER, 2018-2030 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 132. DENMARK DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. DENMARK DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 134. DENMARK DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 135. DENMARK DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CANCER SCREENING, 2018-2030 (USD MILLION)
  • TABLE 136. DENMARK DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY HEREDITARY CANCER, 2018-2030 (USD MILLION)
  • TABLE 137. EGYPT DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. EGYPT DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 139. EGYPT DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 140. EGYPT DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CANCER SCREENING, 2018-2030 (USD MILLION)
  • TABLE 141. EGYPT DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY HEREDITARY CANCER, 2018-2030 (USD MILLION)
  • TABLE 142. FINLAND DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. FINLAND DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 144. FINLAND DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 145. FINLAND DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CANCER SCREENING, 2018-2030 (USD MILLION)
  • TABLE 146. FINLAND DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY HEREDITARY CANCER, 2018-2030 (USD MILLION)
  • TABLE 147. FRANCE DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. FRANCE DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 149. FRANCE DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 150. FRANCE DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CANCER SCREENING, 2018-2030 (USD MILLION)
  • TABLE 151. FRANCE DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY HEREDITARY CANCER, 2018-2030 (USD MILLION)
  • TABLE 152. GERMANY DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 153. GERMANY DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 154. GERMANY DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 155. GERMANY DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CANCER SCREENING, 2018-2030 (USD MILLION)
  • TABLE 156. GERMANY DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY HEREDITARY CANCER, 2018-2030 (USD MILLION)
  • TABLE 157. ISRAEL DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 158. ISRAEL DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 159. ISRAEL DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 160. ISRAEL DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CANCER SCREENING, 2018-2030 (USD MILLION)
  • TABLE 161. ISRAEL DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY HEREDITARY CANCER, 2018-2030 (USD MILLION)
  • TABLE 162. ITALY DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 163. ITALY DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 164. ITALY DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 165. ITALY DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CANCER SCREENING, 2018-2030 (USD MILLION)
  • TABLE 166. ITALY DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY HEREDITARY CANCER, 2018-2030 (USD MILLION)
  • TABLE 167. NETHERLANDS DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 168. NETHERLANDS DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 169. NETHERLANDS DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 170. NETHERLANDS DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CANCER SCREENING, 2018-2030 (USD MILLION)
  • TABLE 171. NETHERLANDS DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY HEREDITARY CANCER, 2018-2030 (USD MILLION)
  • TABLE 172. NIGERIA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 173. NIGERIA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 174. NIGERIA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 175. NIGERIA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CANCER SCREENING, 2018-2030 (USD MILLION)
  • TABLE 176. NIGERIA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY HEREDITARY CANCER, 2018-2030 (USD MILLION)
  • TABLE 177. NORWAY DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 178. NORWAY DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 179. NORWAY DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 180. NORWAY DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CANCER SCREENING, 2018-2030 (USD MILLION)
  • TABLE 181. NORWAY DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY HEREDITARY CANCER, 2018-2030 (USD MILLION)
  • TABLE 182. POLAND DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 183. POLAND DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 184. POLAND DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 185. POLAND DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CANCER SCREENING, 2018-2030 (USD MILLION)
  • TABLE 186. POLAND DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY HEREDITARY CANCER, 2018-2030 (USD MILLION)
  • TABLE 187. QATAR DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 188. QATAR DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 189. QATAR DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 190. QATAR DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CANCER SCREENING, 2018-2030 (USD MILLION)
  • TABLE 191. QATAR DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY HEREDITARY CANCER, 2018-2030 (USD MILLION)
  • TABLE 192. RUSSIA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 193. RUSSIA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 194. RUSSIA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 195. RUSSIA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CANCER SCREENING, 2018-2030 (USD MILLION)
  • TABLE 196. RUSSIA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY HEREDITARY CANCER, 2018-2030 (USD MILLION)
  • TABLE 197. SAUDI ARABIA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 198. SAUDI ARABIA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 199. SAUDI ARABIA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 200. SAUDI ARABIA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CANCER SCREENING, 2018-2030 (USD MILLION)
  • TABLE 201. SAUDI ARABIA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY HEREDITARY CANCER, 2018-2030 (USD MILLION)
  • TABLE 202. SOUTH AFRICA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 203. SOUTH AFRICA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 204. SOUTH AFRICA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 205. SOUTH AFRICA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CANCER SCREENING, 2018-2030 (USD MILLION)
  • TABLE 206. SOUTH AFRICA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY HEREDITARY CANCER, 2018-2030 (USD MILLION)
  • TABLE 207. SPAIN DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 208. SPAIN DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 209. SPAIN DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 210. SPAIN DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CANCER SCREENING, 2018-2030 (USD MILLION)
  • TABLE 211. SPAIN DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY HEREDITARY CANCER, 2018-2030 (USD MILLION)
  • TABLE 212. SWEDEN DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 213. SWEDEN DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 214. SWEDEN DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 215. SWEDEN DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CANCER SCREENING, 2018-2030 (USD MILLION)
  • TABLE 216. SWEDEN DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY HEREDITARY CANCER, 2018-2030 (USD MILLION)
  • TABLE 217. SWITZERLAND DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 218. SWITZERLAND DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 219. SWITZERLAND DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 220. SWITZERLAND DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CANCER SCREENING, 2018-2030 (USD MILLION)
  • TABLE 221. SWITZERLAND DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY HEREDITARY CANCER, 2018-2030 (USD MILLION)
  • TABLE 222. TURKEY DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 223. TURKEY DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 224. TURKEY DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 225. TURKEY DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CANCER SCREENING, 2018-2030 (USD MILLION)
  • TABLE 226. TURKEY DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY HEREDITARY CANCER, 2018-2030 (USD MILLION)
  • TABLE 227. UNITED ARAB EMIRATES DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 228. UNITED ARAB EMIRATES DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 229. UNITED ARAB EMIRATES DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 230. UNITED ARAB EMIRATES DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CANCER SCREENING, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED ARAB EMIRATES DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY HEREDITARY CANCER, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED KINGDOM DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED KINGDOM DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 234. UNITED KINGDOM DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 235. UNITED KINGDOM DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CANCER SCREENING, 2018-2030 (USD MILLION)
  • TABLE 236. UNITED KINGDOM DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY HEREDITARY CANCER, 2018-2030 (USD MILLION)
  • TABLE 237. DIRECT-TO-CONSUMER GENETIC TESTING MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 238. DIRECT-TO-CONSUMER GENETIC TESTING MARKET, FPNV POSITIONING MATRIX, 2023